Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine.

PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: National Cancer Institute (NCI)
• Treatments: Rosiglitazone

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of differentiated thyroid cancer

• Locoregionally extensive and/or metastatic disease

• Inoperable disease

• Failed prior conventional therapy that included total/near-total thyroidectomy AND radioactive iodine I 131 ablation therapy

• Elevated thyroglobulin (Tg) levels (> 3 ng/mL on thyroid hormone OR > 10 ng/mL off thyroid hormone)

• Tg-antibody positive patients are eligible despite the Tg level

• Radioactive iodine (RAI) scan showing no or therapeutically insignificant (< 1%) RAI uptake after thyroid hormone withdrawal

• Scan performed within the past 18 months

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Hemoglobin ≥ 10 g/dL

• WBC ≥ 3,000/mm^3

• Platelet count ≥ 50,000/mm^3

Hepatic

• ALT ≤ 2 times upper limit of normal

Renal

• Creatinine ≤ 1.5 mg/dL

Cardiovascular

• No New York Heart Association class III or IV cardiac disease

Other

• Not pregnant

• No nursing within the past 3 months

• Negative pregnancy test

• Fertile patients must use effective contraception

• No allergy to thiazolidinediones

• No other malignancy except basal cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• More than 3 months since prior chemotherapy

Endocrine therapy

• See Disease Characteristics

• No concurrent levothyroxine

Radiotherapy

• See Disease Characteristics

• No prior cumulative dose of radioiodine ≥ 800 mCi

• Prior adjuvant or therapeutic external beam radiotherapy allowed

Surgery

• See Disease Characteristics